Helmholtz Gemeinschaft


Browse by Research Team

Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Item Type | Source
Jump to: 2021 | 2020 | 2019 | 2015 | 2014


The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma.
Heider, M. and Eichner, R. and Stroh, J. and Morath, V. and Kuisl, A. and Zecha, J. and Lawatscheck, J. and Baek, K. and Garz, A.K. and Rudelius, M. and Deuschle, F.C. and Keller, U. and Lemeer, S. and Verbeek, M. and Götze, K.S. and Skerra, A. and Weber, W.A. and Buchner, J. and Schulman, B.A. and Kuster, B. and Fernández-Sáiz, V. and Bassermann, F.
Molecular Cell 10 February 2021 (In Press)

The SUMO pathway in pancreatic cancer: insights and inhibition.
Schneeweis, C. and Hassan, Z. and Schick, M. and Keller, U. and Schneider, G.
British Journal of Cancer 124 (3): 531-538. 2 February 2021

Assessment of coronary artery disease during hospitalization for cancer treatment.
Mrotzek, S.M. and Lena, A. and Hadzibegovic, S. and Ludwig, R. and Al-Rashid, F. and Mahabadi, A.A. and Mincu, R.I. and Michel, L. and Johannsen, L. and Hinrichs, L. and Schuler, M. and Keller, U. and Anker, S.D. and Landmesser, U. and Rassaf, T. and Anker, M.S. and Totzeck, M.
Clinical Research in Cardiology 110 (2): 200-210. February 2021

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann, P. and Plütschow, A. and Kobe, C. and Greil, R. and Meissner, J. and Topp, M.S. and Ostermann, H. and Dierlamm, J. and Mohm, J. and Thiemer, J. and Sökler, M. and Kerkhoff, A. and Ahlborn, M. and Halbsguth, T.V. and Martin, S. and Keller, U. and Balabanov, S. and Pabst, T. and Vogelhuber, M. and Hüttmann, A. and Wilhelm, M. and Zijlstra, J.M. and Moccia, A. and Kuhnert, G. and Bröckelmann, P.J. and von Tresckow, B. and Fuchs, M. and Klimm, B. and Rosenwald, A. and Eich, H. and Baues, C. and Marnitz, S. and Hallek, M. and Diehl, V. and Dietlein, M. and Engert, A.
Lancet Oncology 22 (2): 223-234. February 2021

Early response to first-line anti-PD-1 treatment in Hodgkin lymphoma: a PET-based analysis from the prospective, randomized phase II NIVAHL trial.
Voltin, C.A. and Mettler, J. and van Heek, L. and Goergen, H. and Müller, H. and Baues, C. and Keller, U. and Meissner, J. and Trautmann-Grill, K. and Kerkhoff, A. and Fuchs, M. and Sasse, S. and von Tresckow, B. and Dietlein, M. and Borchmann, P. and Engert, A. and Kobe, C. and Bröckelmann, P.J.
Clinical Cancer Research 27 (2): 402-407. January 2021


A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Schmitz, N. and Truemper, L.H. and Bouabdallah, K. and Ziepert, M. and Leclerc, M. and Cartron, G. and Jaccard, A. and Reimer, P. and Wagner-Drouet, E.M. and Wilhelm, M. and Sanhes, L. and Lamy, T. and de Leval, L. and Rosenwald, A. and Roussel, M. and Kroschinsky, F.P. and Lindemann, W.W. and Dreger, P. and Viardot, A. and Milpied, N.J. and Gisselbrecht, C. and Wulf, G.G. and Gyan, E. and Gaulard, P. and Bay, J.O. and Glass, B. and Poeschel, V. and Damaj, G. and Sibon, D. and Delmer, A.J. and Bilger, K. and Banos, A. and Haenel, M. and Dreyling, M. and Metzner, B. and Keller, U. and Braulke, F. and Friedrichs, B. and Nickelsen, M. and Altmann, B. and Tournilhac, O.
Blood 17 December 2020 (In Press)

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1.
Reinke, S. and Bröckelmann, P.J. and Iaccarino, I. and Garcia-Marquez, M. and Borchmann, S. and Jochims, F. and Kotrova, M. and Pal, K. and Brüggemann, M. and Hartmann, E. and Sasse, S. and Kobe, C. and Mathas, S. and Soekler, M. and Keller, U. and Bormann, M. and Zimmermann, A. and Richter, J. and Fuchs, M. and von Tresckow, B. and Borchmann, P. and Schlößer, H. and von Bergwelt-Baildon, M. and Rosenwald, A. and Engert, A. and Klapper, W.
Blood 136 (25): 2851-2863. 17 December 2020

Ubiquitination and ubiquitin-like modifications in multiple myeloma: biology and therapy.
Wirth, M. and Schick, M. and Keller, U. and Krönke, J.
Cancers 12 (12): 3764. 14 December 2020

Authentication of primary murine cell lines by a microfluidics-based lab-on-chip system.
Hong, Y. and Singh, N. and Bamopoulos, S. and Gjerga, E. and Schmalbrock, L.K. and Balabanian, K. and Schick, M. and Keller, U. and Wirth, M.
Biomedicines 8 (12): 590. 9 December 2020

CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma.
Herhaus, P. and Lipkova, J. and Lammer, F. and Yakushev, I. and Vag, T. and Slotta-Huspenina, J. and Habringer, S. and Lapa, C. and Pukrop, T. and Hellwig, D. and Wiestler, B. and Buck, A.K. and Deckert, M. and Wester, H.J. and Bassermann, F. and Schwaiger, M. and Weber, W.A. and Menze, B. and Keller, U.
Journal of Nuclear Medicine 61 (12): 1765-1771. 1 December 2020

First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A - results of a retrospective analysis.
Pouyiourou, M. and Meyer, A. and Stroux, A. and Viardot, A. and La Rosée, P. and Maschmeyer, G. and Kämpfe, D. and Kahl, C. and Vucinic, V. and Monecke, A. and Hirt, C. and Weber, T. and Meissner, J. and Witzens-Harig, M. and Böttcher, S. and Schmalenberg, H. and Marks, R. and Prange-Krex, G. and Kroschinsky, F. and Hauf, E. and Keller, U. and Koch, K. and Klapper, W. and Herold, M. and Scholz, C.W.
Annals of Hematology 99 (12): 2821-2829. December 2020

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes, K. and Hassan, Z.Z. and Doffo, M.J. and Schneeweis, C. and Lier, S. and Öllinger, R. and Rad, R. and Krämer, O.H. and Keller, U. and Saur, D. and Reichert, M. and Schneider, G. and Wirth, M.
Molecular Oncology 14 (12): 3048-3064. December 2020

A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy?
Rieke, D.T. and Keller, U.
Haematologica 105 (11): 2504-2506. 1 November 2020

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer.
Klinghammer, K. and Politz, O. and Eder, T. and Otto, R. and Raguse, J.D. and Albers, A. and Kaufmann, A. and Tinhofer, I. and Hoffmann, J. and Keller, U. and Keilholz, U.
Oncotarget 11 (41): 3688-3697. 13 October 2020

SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
Biederstädt, A. and Hassan, Z. and Schneeweis, C. and Schick, M. and Schneider, L. and Muckenhuber, A. and Hong, Y. and Siegers, G. and Nilsson, L. and Wirth, M. and Dantes, Z. and Steiger, K. and Schunck, K. and Langston, S. and Lenhof, H.P. and Coluccio, A. and Orben, F. and Slawska, J. and Scherger, A. and Saur, D. and Müller, S. and Rad, R. and Weichert, W. and Nilsson, J. and Reichert, M. and Schneider, G. and Keller, U.
Gut 69 (8): 1472-1482. August 2020

Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes, K. and Hassan, Z. and Doffo, M.J. and Schneeweis, C. and Lier, S. and Öllinger, R. and Rad, R. and Krämer, O.H. and Keller, U. and Saur, D. and Reichert, M. and Schneider, G. and Wirth, M.
bioRxiv : 2020.07.01.182162. 2 July 2020

Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial.
Bröckelmann, P.J. and Goergen, H. and Keller, U. and Meissner, J. and Ordemann, R. and Halbsguth, T.V. and Sasse, S. and Sökler, M. and Kerkhoff, A. and Mathas, S. and Hüttmann, A. and Bormann, M. and Zimmermann, A. and Mettler, J. and Fuchs, M. and von Tresckow, B. and Baues, C. and Rosenwald, A. and Klapper, W. and Kobe, C. and Borchmann, P. and Engert, A.
JAMA Oncology 6 (6): 872-880. June 2020

Final results of a phase I/II trial of the combination Bendamustine and Rituximab with Temsirolimus (BeRT) in relapsed mantle cell lymphoma and follicular lymphoma.
Hess, G. and Wagner, K. and Keller, U. and La Rosee, P. and Atta, J. and Hübel, K. and Lerchenmueller, C. and Schoendube, D. and Witzens-Harig, M. and Ruckes, C. and Medler, C. and van Oordt, C. and Klapper, W. and Theobald, M. and Dreyling, M.
HemaSphere 4 (3): e398. June 2020


Age-related gliosis promotes central nervous system lymphoma through CCL19-mediated tumor cell retention.
O'Connor, T. and Zhou, X. and Kosla, J. and Adili, A. and Garcia Beccaria, M. and Kotsiliti, E. and Pfister, D. and Johlke, A.L. and Sinha, A. and Sankowski, R. and Schick, M. and Lewis, R. and Dokalis, N. and Seubert, B. and Höchst, B. and Inverso, D. and Heide, D. and Zhang, W. and Weihrich, P. and Manske, K. and Wohlleber, D. and Anton, M. and Hoellein, A. and Seleznik, G. and Bremer, J. and Bleul, S. and Augustin, H.G. and Scherer, F. and Koedel, U. and Weber, A. and Protzer, U. and Förster, R. and Wirth, T. and Aguzzi, A. and Meissner, F. and Prinz, M. and Baumann, B. and Höpken, U.E. and Knolle, P.A. and von Baumgarten, L. and Keller, U. and Heikenwalder, M.
Cancer Cell 36 (3): 250-267. 16 September 2019


In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma.
Philipp-Abbrederis, K. and Herrmann, K. and Knop, S. and Schottelius, M. and Eiber, M. and Lückerath, K. and Pietschmann, E. and Habringer, S. and Gerngroß, C. and Franke, K. and Rudelius, M. and Schirbel, A. and Lapa, C. and Schwamborn, K. and Steidle, S. and Hartmann, E. and Rosenwald, A. and Kropf, S. and Beer, A.J. and Peschel, C. and Einsele, H. and Buck, An.K. and Schwaiger, M. and Götze, K. and Wester, H.J. and Keller, U.
EMBO Molecular Medicine 7 (4): 477-487. 1 April 2015


GP130 activation induces myeloma and collaborates with MYC.
Dechow, T. and Steidle, S. and Götze, K.S. and Rudelius, M. and Behnke, K. and Pechloff, K. and Kratzat, S. and Bullinger, L. and Fend, F. and Soberon, V. and Mitova, N. and Li, Z. and Thaler, M. and Bauer, J. and Pietschmann, E. and Albers, C. and Grundler, R. and Schmidt-Supprian, M. and Ruland, J. and Peschel, C. and Duyster, J. and Rose-John, S. and Bassermann, F. and Keller, U.
Journal of Clinical Investigation 124 (12): 5263-5274. 1 December 2014

Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein, A. and Fallahi, M. and Schoeffmann, S. and Steidle, S. and Schaub, F.X. and Rudelius, M. and Laitinen, I. and Nilsson, L. and Goga, A. and Peschel, C. and Nilsson, J.A. and Cleveland, J.L. and Keller, U.
Blood 124 (13): 2081-2090. 25 September 2014

This list was generated on Sun Mar 7 02:21:33 2021 CET.
Open Access
MDC Library